Table 1.

Response rates to erlotinib and gefitinib in different patient subgroups treated in randomized clinical trials (9, 10)

GroupErlotinib (BR.21)
Gefitinib (ISEL)
Response rate (%)PResponse rate (%)P
Women vs men14 vs 60.00615 vs 5NR
Adenocarcinoma vs other histologies14 vs 4<0.00112 vs 5NR
Asian vs non-Asian19 vs 80.0212 vs 7NR
Never smoker vs current/former25 vs 4<0.00118 vs 5NR
  • Abbreviations: NR, not reported; ISEL, Iressa Survival Evaluation in Lung Cancer.